Comparison between the SAPIEN S3 and the SAPIEN XT transcatheter heart valves: A single-center experience

Table 3 Thirty-day and 1-year outcomes

30-d outcomes	S3-THV (n =283)	XT-THV (n = 507)	Odds ratio (95%CI)	P value	Adjusted odds ratio (95%CI)	Adjusted P value
Death	8 (3.5)	42 (8.7)	0.36 (0.16-0.81)	0.01	0.44 (0.12-1.56)	0.21
Stroke	4 (1.4)	13 (2.8)	0.51 (0.16-1.58)	0.24	0.59 (0.08-4.33)	0.6
Myocardial infarction	0 (0)	2 (0.4)	0 (0-∞)	1
New pacemaker implantation1	43 (17.3)	44 (9.8)	1.88 (1.19-2.97)	0.007	1.68 (1.05-2.69)	0.03
Major vascular complication	8 (2.8)	50 (9.9)	0.27 (0.13-0.57)	0.001	0.20 (0.09-0.44)	< 0.0001
Paravalvular regurgitation > mild	6 (2.4)	47 (9.7)	0.23 (0.10-0.55)	0.001	0.20 (0.08-0.47)	< 0.0001
Acute kidney injury	3 (1.1)	69 (13.6)	0.07 (0.02-0.22)	< 0.0001	0.12 (0.04-0.39)	< 0.0001
Mean gradient > 20 mmHg	7 (2.8)	6 (1.3)	2.48 (0.78-7.89)	0.13
Mean gradient, mmHg	11.8 ± 5.8	10.0 ± 5.0		< 0.0001
Total hospital length of stay, d [median (IQR)]	8 [5-13]	9 [7-14]		< 0.0001
1-yr outcomes				P value	Adjusted hazard ratio (95%CI)	Adjusted P value
Death	20 (25.7)	87 (20.1)		0.24	0.86 (0.52-1.42)	0.55

Values are mean ± SD or n (%) unless specified otherwise.

¹Patients with previous permanent pacemaker were excluded from this analysis. No adjusted analyses were performed for outcomes with less than 15 events overall. IQR: Inter-quartile range; S3-THV: SAPIEN 3 transcatheter heart valve; XT-THV: SAPIEN XT transcatheter heart valve.